ARPA-H SBIR/STTR funding flagged

ARPA-H’s small-business lane is live again, and the real news is more specific than “aging innovation funding.” The agency has a 2026 SBIR/STTR solicitation in draft form right now, with final posting targeted for June 11, 2026, and early submissions due July 10. But this is not an aging-specific call. It’s a broader health-tech funding round that includes topics like fertility testing, bioadhesives, autoimmune diagnostics, endometriosis therapy, toxin removal, and neurosurgical robotics. ### What actually opened? What’s open today is the pre-solicitation window. ARPA-H has posted the draft solicitation, listed seven open topic areas, and told companies to use this period to prepare before the final solicitation goes live. The agency’s own site says applications are not yet being accepted through the portal for this round, which matters because a lot of social posts blur “draft posted” into “money available now.” (arpa-h.gov) ### Is this really about aging? Not directly. None of the seven listed 2026 topics is framed as “aging” or “older adults” in the solicitation summary. But some are adjacent — especially the multi-system autoimmune diagnostic topic, brain-related tooling, and platform technologies that could later be used in older populations. That makes the aging angle an interpretation, not the official scope of the current call. ### What kind of money is this? (arpa-h.gov) This is SBIR/STTR money, but ARPA-H runs it in a more milestone-heavy, commercialization-oriented way than many people expect from federal R&D programs. The agency says awards are generally issued as contracts of up to $600,000 for Phase I and $3.5 million for Phase II. That is meaningful early capital for a startup that has a real prototype path but is too risky for normal procurement or too applied for traditional academic funding. ### Why does “contracts, not grants” matter? Because ARPA-H is not set up like NIH’s classic grant system. Its site is blunt about that — it mainly uses performance-based agreements, and small-business awards are contracts tied to ambitious milestones. Basically, the government is not just handing over research money and waiting for a paper. ARPA-H wants a build plan, measurable progress, and something that can move toward the market. (arpa-h.gov) ### Who can actually apply? Only eligible small businesses can submit to these SBIR/STTR solicitations. ARPA-H says the company must have no more than 500 employees, be majority U.S.-owned, and perform the work in the U.S. For SBIR, the principal investigator also has to be more than 50% employed by the small business. So nonprofits, university labs, and advocacy groups are not the direct applicants unless they’re teaming with an eligible company under the right structure. (arpa-h.gov) ### What are the dates to watch? The draft says the final solicitation is targeted for June 11, 2026. Solution summaries are due July 10, 2026, and teams that clear that stage move on to a pitch plus full materials due September 9, 2026. ARPA-H also closed the current question window on May 6, with questions set to reopen after the final solicitation posts. ### Has ARPA-H actually funded companies this way before? Yes — and recently. (arpa-h.gov) On April 22, 2026, ARPA-H announced up to $28 million in contracts to 15 small businesses across eight states. Those projects included wearables, AI communication tools, dementia-related support software, sterility testing, and other commercialization-focused health technologies. So this is not a theoretical pipeline. The agency is already making awards and using the program to push products toward market readiness. ### So what’s the bottom line? The useful read on this story is not “ARPA-H launched an aging call.” It’s that ARPA-H has a live 2026 SBIR/STTR pipeline, the current topics are broader than aging, and small health-tech companies have a short runway to get ready before the final solicitation lands in June. (arpa-h.gov 1) (arpa-h.gov 2)